Repligen Corporation (RGEN) Social Stream



Repligen Corporation (RGEN): $173.62

5.17 (+3.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

Repligen Corp (RGEN) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Repligen Corp.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-02 10 $368 $240 $312.555 $167.02 87.14%
2021-12-20 10 $368 $240 $315.888 $167.02 89.13%
2022-02-18 10 $368 $240 $310.333 $167.02 85.81%
2022-03-01 10 $368 $210 $281.444 $167.02 68.51%

The Trend in the Analyst Price Target


RGEN's average price target has moved up $142.3 over the prior 21 months.

Over the past 49 weeks, RGEN's average upside potential has been 19.81%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-06-05 5 251 200 238.860 177.79 34.35%
2021-07-03 5 251 200 238.860 201.90 18.31%
2021-09-18 5 335 232 267.880 306.90 -12.71%
2021-11-02 10 368 240 312.555 302.73 3.25%
2022-02-18 10 368 240 310.333 180.68 71.76%

RGEN Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.2 9 0 1 0 0 10

The Trend in the Broker Recommendations


Over the past 28 days, RGEN's average broker recommendation rating improved by 0.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • In the context of all US stocks, Repligen Corp's average analyst price target is greater than 564.4% of them.
  • Repligen Corp's upside potential (average analyst target price relative to current price) is higher than 491.24% of stocks in the large market cap category.
  • RGEN has a greater number of analysts covering the stock than 476.34% of Pharmaceutical Products stocks.
  • Repligen Corp's variance in analysts' estimates is lower than -264.28% of stocks in the large market cap category.

Stocks similar to Repligen Corp in the Pharmaceutical Products industry regarding analyst recommendations and price targets are QGEN, NVAX, and NBIX.

Make investment decisions regarding RGEN using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4733 seconds.